Growth hormone secretagogues are among the most searched — and most misunderstood — categories in peptide research. The name sounds like one kind of compound, but it actually spans two distinct families that stimulate growth hormone (GH) release through entirely different receptors. Understanding that split — GHRH-pathway agonists versus ghrelin-receptor agonists — is the key to making sense of compounds like CJC-1295 and ipamorelin.
This beginner’s guide maps the territory: how the GH axis works, what the two classes are, why they are studied together, and what the evidence and regulators actually say. For compound-level detail, see our guides to CJC-1295 and ipamorelin.
Research Use Only — Not for Human Consumption: Vonox Labs products are intended strictly for laboratory and research purposes. This article is educational content only and is not medical advice. Nothing here is a dosing instruction or a recommendation for human use.
How the GH Axis Works
Growth hormone secretion is governed by a compact feedback circuit:
- The hypothalamus issues commands. It releases GHRH, which tells the pituitary to release GH, and somatostatin, which tells it to stop. These opposing signals set the rhythm.
- The anterior pituitary responds. GHRH binds receptors on somatotroph cells, triggering GH release in episodic pulses — the largest typically occurring shortly after sleep onset. Pulsatility is central to GH physiology.
- The liver translates the signal. GH drives hepatic production of IGF-1 (insulin-like growth factor 1), the downstream mediator of much of GH’s metabolic and growth-related signaling.
- Feedback closes the loop. Rising GH and IGF-1 increase somatostatin tone, suppressing further release — the “brake” that keeps the system regulated.
There is also an amplifier circuit: the stomach-derived hormone ghrelin, discovered in 1999, binds the growth hormone secretagogue receptor (GHS-R1a) in the hypothalamus and pituitary, boosting GH release and modulating GHRH and somatostatin tone.
Every compound in this article acts somewhere on this axis — never by supplying GH directly, but by engaging one of its command pathways.
What the Term “Secretagogue” Actually Covers
A secretagogue is simply a substance that causes another substance to be secreted — so strictly speaking, any compound researched for stimulating GH release is a growth hormone secretagogue, including GHRH analogs.
In practice the literature uses the term two ways. The broad sense covers everything below. The narrower usage — “GHS” (growth hormone secretagogues) — denotes the ghrelin-receptor class: the GHRPs, ipamorelin, and oral small molecules like MK-677. These were developed by reverse pharmacology in the 1980s–90s, before ghrelin or its receptor had even been identified (Smith, 2005).
That dual usage causes most of the confusion: “GHRH vs GHRP” is really a comparison of two receptor systems — the GHRH receptor and the ghrelin receptor — each with its own family of research compounds.
Class 1: GHRH-Pathway Agonists
These mimic the hypothalamus’s own stimulatory signal. They bind the GHRH receptor (GHRHR) on pituitary somatotrophs, activating cAMP signaling that drives GH release — while leaving the somatostatin feedback brake engaged, a distinction researchers have studied as relevant to the physiology of axis stimulation.
- CJC-1295 — a stabilized 29-amino-acid GHRH analog; in its DAC form it binds serum albumin, extending a minutes-long signal into a days-long research tool. Early human studies reported sustained, pulsatile GH release and multi-day IGF-1 elevation (Teichman, 2006; Ionescu, 2006).
- Tesamorelin — a stabilized GHRH analog and the rare exception in this space: FDA approved as Egrifta for excess abdominal fat in HIV-associated lipodystrophy in November 2010 (Grunfeld, 2011). Its approval is the exception that proves the rule about the rest of the class.
- Sermorelin — GHRH(1-29) itself, a shorter-acting research and former diagnostic compound.
Key Takeaway: GHRH-pathway agonists work with the pituitary’s existing machinery — amplifying the hypothalamus’s own command rather than bypassing it — which is why researchers emphasize the preservation of natural GH pulsatility in this class.
Class 2: Ghrelin-Receptor (GHS) Agonists
The second family acts on the growth hormone secretagogue receptor type 1a (GHS-R1a) — the ghrelin receptor — in the pituitary and hypothalamus. These compounds were discovered before their receptor or natural ligand was known, a textbook case of reverse pharmacology (Smith, 2005).
- Ipamorelin — a synthetic pentapeptide described in 1998 as “the first selective growth hormone secretagogue,” developed by Novo Nordisk to separate GH release from the cortisol, ACTH, and prolactin effects of earlier compounds (Raun, 1998).
- GHRP-2 and GHRP-6 — earlier-generation secretagogues that potently release GH but were reported to stimulate ACTH, cortisol, and prolactin alongside it — the hormonal noise ipamorelin was designed to avoid.
- Hexarelin — another early GHRP with a similarly broad hormonal profile.
- MK-677 (ibutamoren) — an orally active non-peptide GHS, the small-molecule outlier in a peptide-dominated class; studied in human trials, but never approved.
Because the ghrelin receptor is expressed beyond the pituitary — in appetite, gut-motility, and cardiovascular pathways — selectivity differences within this class matter greatly when interpreting studies.
GHRH vs GHRP Side by Side
| GHRH-pathway agonists | Ghrelin-receptor (GHS) agonists | |
|---|---|---|
| Receptor | GHRH receptor (GHRHR) on pituitary somatotrophs | Growth hormone secretagogue receptor 1a (GHS-R1a) in pituitary and hypothalamus |
| Natural ligand mimicked | Hypothalamic GHRH | Ghrelin (stomach-derived, discovered 1999) |
| Example compounds | CJC-1295, tesamorelin, sermorelin | Ipamorelin, GHRP-2, GHRP-6, hexarelin, MK-677 |
| Selectivity considerations | Generally GH-axis specific; GHRH signaling also intersects sleep biology | Older GHRPs stimulate ACTH, cortisol, and prolactin alongside GH; ipamorelin is the most GH-selective; receptor is widely expressed (appetite, gut, heart) |
| Research status | Tesamorelin is FDA approved (Egrifta); CJC-1295 discontinued after early-phase human studies | Macimorelin approved as an adult GH-deficiency diagnostic; ipamorelin discontinued after early-phase studies; MK-677 studied in humans but never approved |
Why Researchers Study Both Together
One of the most replicated findings in GH-axis literature is the synergy between the two pathways: co-stimulating the GHRH receptor and the ghrelin receptor releases GH supra-additively — more than the sum of either alone. This has been documented across many compound pairings since the 1980s (Bowers, 1998; Smith, 2005).
That pathway-level synergy is why CJC-1295 and ipamorelin are so frequently discussed together: one compound engages each receptor, letting investigators probe both natural GH-release pathways simultaneously. What the literature establishes is a property of the two pathways, not a validated combined protocol — the specific pairings have not been tested in formal clinical trials.
What the Evidence Actually Supports (and Its Limits)
The honest summary of the human evidence:
- GHRH-pathway stimulation works as advertised in short studies. Single administrations of long-acting CJC-1295 in healthy adults produced dose-dependent GH elevation for days and IGF-1 increases lasting over a week, with natural pulsatility preserved (Teichman, 2006; Ionescu, 2006).
- Selective ghrelin-receptor agonism is achievable. Ipamorelin released GH with potency comparable to GHRP-6 but markedly less ACTH and cortisol stimulation in its landmark characterization (Raun, 1998), and advanced to early-phase human investigation.
- One compound crossed the regulatory finish line. Tesamorelin’s phase 3 program in HIV-associated lipodystrophy led to FDA approval — proof that GHRH-pathway pharmacology can clear the clinical bar (Grunfeld, 2011; Dhillon, 2011).
And the limits, stated plainly:
First, for most compounds here the human evidence is early-phase and short-term. CJC-1295 and ipamorelin never advanced past early studies; their programs were discontinued.
Second, no published trial has evaluated these compounds for body-composition, performance, or disease-related endpoints in the way non-scientific discussion often implies. Mechanistic rationale is not demonstrated outcomes.
Third, selectivity varies enormously within the GHS class. Findings from ipamorelin do not transfer to GHRP-6 or hexarelin, yet informal discussion routinely treats “GHRPs” as interchangeable.
Regulatory Reality
- CJC-1295 is not FDA approved for any indication, and no CJC-1295 drug product has been approved anywhere. Its development program was discontinued after early-phase studies.
- Ipamorelin, GHRP-2, GHRP-6, hexarelin, and MK-677 are not FDA approved for any indication.
- The exceptions that prove the rule: tesamorelin (Egrifta), a GHRH analog FDA approved in November 2010 for excess abdominal fat in HIV-associated lipodystrophy (Grunfeld, 2011), and macimorelin, an oral ghrelin-receptor agonist approved as a diagnostic test for adult growth hormone deficiency (Garcia, 2018).
- Like other GH-axis compounds, these peptides fall within broad prohibited categories in sports anti-doping frameworks.
Approval of tesamorelin and macimorelin does not change the status of anything else in this article: the research compounds discussed here remain research compounds.
Frequently Asked Questions
What does the term “growth hormone secretagogue” actually cover?
Any compound researched for stimulating GH release. In practice the label is used both broadly (including GHRH analogs) and narrowly for the ghrelin-receptor class (GHRPs, ipamorelin, MK-677). When precision matters, specify the receptor: GHRH receptor or GHS-R1a.
What’s the difference between GHRH and GHRP compounds?
They stimulate GH through different receptors. GHRH analogs like CJC-1295 mimic the hypothalamus’s stimulatory signal at the GHRH receptor; GHRPs like ipamorelin mimic ghrelin at the GHS-R1a receptor. Both converge on pituitary somatotrophs through separate signaling pathways.
Are secretagogues the same as taking HGH?
No. Secretagogues prompt the pituitary to release its own GH through the body’s command pathways, leaving somatostatin-mediated feedback engaged. Direct GH administration supplies the hormone itself, bypassing those regulatory loops. Researchers treat these as physiologically distinct approaches.
Are any growth hormone secretagogues FDA approved?
Two are. Tesamorelin (Egrifta), a GHRH analog, was FDA approved in 2010 for excess abdominal fat in HIV-associated lipodystrophy. Macimorelin, an oral ghrelin-receptor agonist, is approved as a diagnostic test for adult GH deficiency. CJC-1295, ipamorelin, the GHRPs, and MK-677 are not approved.
Why are CJC-1295 and ipamorelin studied together?
Because they engage the two GH-release pathways through different receptors — CJC-1295 at the GHRH receptor, ipamorelin at the ghrelin receptor — and decades of research document that the two pathways release GH synergistically. They are complementary research tools, not a validated combined protocol.
The Bottom Line
“Growth hormone secretagogue” is an umbrella term for two distinct research toolkits — GHRH-pathway agonists that amplify the hypothalamus’s own command, and ghrelin-receptor agonists that engage a separate amplifier circuit — each with its own receptor, selectivity profile, and evidence base.
The foundational findings are real: GHRH analogs can drive sustained, pulsatile GH release; selective ghrelin-receptor agonism is achievable; the two pathways synergize; and tesamorelin proves the pharmacology can reach approval. But for most compounds the evidence stops at early-phase pharmacology, the discontinued programs never produced outcome data, and non-scientific discussion routinely outruns what was actually measured.
For researchers, this literature is a map of GH-axis biology — two receptors, one feedback circuit, and a handful of well-characterized probes — not a shortcut around the evidence that was never generated.
Explore Our GH-Axis Research Peptides
Learn more about CJC-1295 and Ipamorelin and explore our research-focused peptides at Vonox Labs: CJC-1295 and Ipamorelin
Research. Test. Learn.
Ver materiales de investigación: Tienda VONOX Labs
Research Use Only: Vonox Labs products are intended strictly for laboratory and research purposes and are not intended for human or veterinary consumption. This information is provided for educational purposes only and is not medical advice.
Scientific References
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. (Single-dose human study of the DAC form; dose-dependent GH elevation for 6+ days and IGF-1 increases for 9–11 days.) https://pubmed.ncbi.nlm.nih.gov/16352683/
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-7. (GH pulsatility preserved during sustained GHRH-receptor stimulation; trough GH markedly increased.) https://pubmed.ncbi.nlm.nih.gov/17018654/
- Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. (Landmark characterization: potent GH release with minimal ACTH/cortisol stimulation versus earlier GHRPs.) https://pubmed.ncbi.nlm.nih.gov/9849822/
- Bowers CY. Growth hormone-releasing peptide (GHRP). Cell Mol Life Sci. 1998;54(12):1316-29. (Foundational review of the GHRP class, its hypothalamic-pituitary action, and GHRH/GHRP synergy in GH release.) https://pubmed.ncbi.nlm.nih.gov/9893708/
- Smith RG. Development of growth hormone secretagogues. Endocr Rev. 2005;26(3):346-60. (Review of GHS reverse pharmacology, ghrelin-receptor biology, and clinical development programs including MK-677.) https://pubmed.ncbi.nlm.nih.gov/15814848/
- Grunfeld C, Dritselis A, Kirkpatrick P. Tesamorelin. Nat Rev Drug Discov. 2011;10(2):95-6. (FDA approval of tesamorelin (Egrifta), a GHRH analog, in November 2010 for excess abdominal fat in HIV-associated lipodystrophy.) https://pubmed.ncbi.nlm.nih.gov/21283099/
- Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011;71(8):1071-91. (Review of tesamorelin pharmacology and its phase 3 trial program.) https://pubmed.ncbi.nlm.nih.gov/21668043/
- Garcia JM, Biller BMK, Korbonits M, Popovic V, Luger A, Strasburger CJ, Chanson P, Medic-Stojanoska M, Schopohl J, Zakrzewska A, Pekic S, Bolanowski M, Swerdloff R, Wang C, Blevins T, Marcelli M, Ammer N, Sachse R, Yuen KCJ. Macimorelin as a Diagnostic Test for Adult GH Deficiency. J Clin Endocrinol Metab. 2018;103(8):3083-3093. (Validation of oral macimorelin, an approved ghrelin-receptor agonist, as a GH-deficiency diagnostic.) https://pubmed.ncbi.nlm.nih.gov/29860473/
Leave a Reply